Radiotracer and antibody-drug conjugate (ADC) development both demand precision. But how confident can teams be that the molecule is hitting the right target, in the right tumors, at the right time?
This webinar is designed specifically for teams developing ADCs or biologics aiming to make faster, more informed go/no-go decisions. Learn how radiolabeling provides real-time biodistribution data across clinically relevant patient-derived xenograft (PDX) models — revealing precisely where it’s going, how much it reaches the tumor and whether the targeting is genuinely effective.
Join the featured speakers to explore:
- Real-world examples of how radiolabeled ADCs and biologics are being applied in preclinical research today
- Scientific considerations for transitioning from standard ADC payloads to radiolabeled approaches
- How imaging-based targeting validation can align R&D goals with regulatory and clinical expectations
Register for this webinar to discover how radiotracers and ADC targeting strategies can improve preclinical decision-making and enhance translational success.
Speakers
Dr. Shankar Vallabhajosula, PhD, Professor of Radiochemistry and Radiopharmacy, Weill Cornell Medical College
Shankar Vallabhajosula received his BS and MS degrees in Pharmaceutical Sciences from Andhra University (1969 and 1971), Visakhapattanam. After working for a couple of years at Biological Evans, Hyderabad, and All-India Institute of Medical Sciences, New Delhi, he immigrated to United States in 1994.
In New York, after working for two years in Nuclear Medicine, he received his board certification as a Nuclear Medicine Technologist in 1976. Subsequently, he pursued graduate studies in Biomedicinal Chemistry/Radiopharmacy from the School of Pharmacy at the University of Southern California, Los Angeles, and received his PhD in 1980.
Read more...
Dr. Vallabhajosula is a Professor Emeritus of Radiochemistry/Radiopharmacy in Radiology at WCM of Cornell University, New York, NY. He also served as the President and Chief Scientific Officer for four years at NCM USA, a radiopharmaceutical manufacturing company for PET and targeted radionuclide therapy. Since February 2023, Dr. Vallabhajosula has served as the Vice President of Radiopharmaceutical Sciences at Convergent Therapeutics Inc., Cambridge, MA.
Dr. Vallabhajosula has been an active member of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and served as an associate editor of the Journal of Nuclear Medicine (1994-1998). For his contributions to the basic and clinical science of nuclear medicine, Dr. Shankar received the Berson and Yalow award in 2007 by the Greater New York Chapter of Nuclear Medicine, and the Lifetime Achievement Award in 2022 by the General Clinical Nuclear Medicine Council of the SNMMI. Dr. Vallabhajosula published two single-author textbooks: “Molecular Imaging: Radiopharmaceuticals for PET and SPECT” (Springer Verlag, 2009) and a second and revised edition “Molecular Imaging and Targeted Therapy: Radiopharmaceuticals and Clinical Applications” (Springer Nature 2023).
Read Less...
Dr. Denis R. Beckford-Vera, PhD, Head of Radiopharmacology, Champions Oncology
Dr. Beckford-Vera specializes in the design, labeling and in vivo characterization of immunoPET and radiotherapeutic agents. His work encompasses novel alpha- and beta-emitting isotopes for targeted oncology, with published success in CD46 and CD33-directed radioimmunotherapies. He brings deep knowledge of tumor imaging, biodistribution and ligand-payload conjugation.
Message PresenterWho Should Attend?
This session is for scientific and strategic leaders at ADC-focused biotechs who need to improve targeting validation and make better decisions before clinical investment. Ideal attendees include:
- Chief Scientific Officers (CSOs) and Heads of R&D looking to reduce late-stage attrition
- Translational Leads and Preclinical Scientists evaluating antibody behavior in vivo
- VPs of Oncology or Targeted Therapeutics seeking better IND-enabling data
- Business Development or Program Strategy Directors considering modality-enhancing tools
- Anyone advancing an ADC or biologic program into preclinical IND-enabling work
- Program Leads managing early-stage ADC or antibody programs nearing go/no-go decision points
What You Will Learn
Attendees will gain insight into:
- How radiotracers (radiolabeled ADCs/biologics) provide preclinical insight into antibody targeting beyond what efficacy alone can show
- How to use biodistribution and imaging studies to select better leads, avoid off-target liabilities and improve clinical confidence
- Why PDX models offer the best platform for translationally relevant targeting data in ADC development
- A practical framework for integrating radiolabeling into an existing preclinical workflow, without rebuilding a program
Xtalks Partner
Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account